Cargando…
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
OBJECTIVE: To evaluate tofacitinib's effect upon pneumococcal and influenza vaccine immunogenicity. METHODS: We conducted two studies in patients with rheumatoid arthritis using the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) and the 2011–2012 trivalent influenza vaccine. In study A...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819610/ https://www.ncbi.nlm.nih.gov/pubmed/25795907 http://dx.doi.org/10.1136/annrheumdis-2014-207191 |
_version_ | 1782425240428609536 |
---|---|
author | Winthrop, Kevin L Silverfield, Joel Racewicz, Arthur Neal, Jeffrey Lee, Eun Bong Hrycaj, Pawel Gomez-Reino, Juan Soma, Koshika Mebus, Charles Wilkinson, Bethanie Hodge, Jennifer Fan, Haiyun Wang, Tao Bingham, Clifton O |
author_facet | Winthrop, Kevin L Silverfield, Joel Racewicz, Arthur Neal, Jeffrey Lee, Eun Bong Hrycaj, Pawel Gomez-Reino, Juan Soma, Koshika Mebus, Charles Wilkinson, Bethanie Hodge, Jennifer Fan, Haiyun Wang, Tao Bingham, Clifton O |
author_sort | Winthrop, Kevin L |
collection | PubMed |
description | OBJECTIVE: To evaluate tofacitinib's effect upon pneumococcal and influenza vaccine immunogenicity. METHODS: We conducted two studies in patients with rheumatoid arthritis using the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) and the 2011–2012 trivalent influenza vaccine. In study A, tofacitinib-naive patients were randomised to tofacitinib 10 mg twice daily or placebo, stratified by background methotrexate and vaccinated 4 weeks later. In study B, patients already receiving tofacitinib 10 mg twice daily (with or without methotrexate) were randomised into two groups: those continuing (‘continuous’) or interrupting (‘withdrawn’) tofacitinib for 2 weeks, and then vaccinated 1 week after randomisation. In both studies, titres were measured 35 days after vaccination. Primary endpoints were the proportion of patients achieving a satisfactory response to pneumococcus (twofold or more titre increase against six or more of 12 pneumococcal serotypes) and influenza (fourfold or more titre increase against two or more of three influenza antigens). RESULTS: In study A (N=200), fewer tofacitinib patients (45.1%) developed satisfactory pneumococcal responses versus placebo (68.4%), and pneumococcal titres were lower with tofacitinib (particularly with methotrexate). Similar proportions of tofacitinib-treated and placebo-treated patients developed satisfactory influenza responses (56.9% and 62.2%, respectively), although fewer tofacitinib patients (76.5%) developed protective influenza titres (≥1:40 in two or more of three antigens) versus placebo (91.8%). In study B (N=183), similar proportions of continuous and withdrawn patients had satisfactory responses to PPSV-23 (75.0% and 84.6%, respectively) and influenza (66.3% and 63.7%, respectively). CONCLUSIONS: Among patients starting tofacitinib, diminished responsiveness to PPSV-23, but not influenza, was observed, particularly in those taking concomitant methotrexate. Among existing tofacitinib users, temporary drug discontinuation had limited effect upon influenza or PPSV-23 vaccine responses. TRIAL REGISTRATION NUMBERS: NCT01359150, NCT00413699. |
format | Online Article Text |
id | pubmed-4819610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-48196102016-04-19 The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis Winthrop, Kevin L Silverfield, Joel Racewicz, Arthur Neal, Jeffrey Lee, Eun Bong Hrycaj, Pawel Gomez-Reino, Juan Soma, Koshika Mebus, Charles Wilkinson, Bethanie Hodge, Jennifer Fan, Haiyun Wang, Tao Bingham, Clifton O Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVE: To evaluate tofacitinib's effect upon pneumococcal and influenza vaccine immunogenicity. METHODS: We conducted two studies in patients with rheumatoid arthritis using the 23-valent pneumococcal polysaccharide vaccine (PPSV-23) and the 2011–2012 trivalent influenza vaccine. In study A, tofacitinib-naive patients were randomised to tofacitinib 10 mg twice daily or placebo, stratified by background methotrexate and vaccinated 4 weeks later. In study B, patients already receiving tofacitinib 10 mg twice daily (with or without methotrexate) were randomised into two groups: those continuing (‘continuous’) or interrupting (‘withdrawn’) tofacitinib for 2 weeks, and then vaccinated 1 week after randomisation. In both studies, titres were measured 35 days after vaccination. Primary endpoints were the proportion of patients achieving a satisfactory response to pneumococcus (twofold or more titre increase against six or more of 12 pneumococcal serotypes) and influenza (fourfold or more titre increase against two or more of three influenza antigens). RESULTS: In study A (N=200), fewer tofacitinib patients (45.1%) developed satisfactory pneumococcal responses versus placebo (68.4%), and pneumococcal titres were lower with tofacitinib (particularly with methotrexate). Similar proportions of tofacitinib-treated and placebo-treated patients developed satisfactory influenza responses (56.9% and 62.2%, respectively), although fewer tofacitinib patients (76.5%) developed protective influenza titres (≥1:40 in two or more of three antigens) versus placebo (91.8%). In study B (N=183), similar proportions of continuous and withdrawn patients had satisfactory responses to PPSV-23 (75.0% and 84.6%, respectively) and influenza (66.3% and 63.7%, respectively). CONCLUSIONS: Among patients starting tofacitinib, diminished responsiveness to PPSV-23, but not influenza, was observed, particularly in those taking concomitant methotrexate. Among existing tofacitinib users, temporary drug discontinuation had limited effect upon influenza or PPSV-23 vaccine responses. TRIAL REGISTRATION NUMBERS: NCT01359150, NCT00413699. BMJ Publishing Group 2016-04 2015-03-20 /pmc/articles/PMC4819610/ /pubmed/25795907 http://dx.doi.org/10.1136/annrheumdis-2014-207191 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Clinical and Epidemiological Research Winthrop, Kevin L Silverfield, Joel Racewicz, Arthur Neal, Jeffrey Lee, Eun Bong Hrycaj, Pawel Gomez-Reino, Juan Soma, Koshika Mebus, Charles Wilkinson, Bethanie Hodge, Jennifer Fan, Haiyun Wang, Tao Bingham, Clifton O The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis |
title | The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis |
title_full | The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis |
title_fullStr | The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis |
title_full_unstemmed | The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis |
title_short | The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis |
title_sort | effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis |
topic | Clinical and Epidemiological Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819610/ https://www.ncbi.nlm.nih.gov/pubmed/25795907 http://dx.doi.org/10.1136/annrheumdis-2014-207191 |
work_keys_str_mv | AT winthropkevinl theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT silverfieldjoel theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT racewiczarthur theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT nealjeffrey theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT leeeunbong theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT hrycajpawel theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT gomezreinojuan theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT somakoshika theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT mebuscharles theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT wilkinsonbethanie theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT hodgejennifer theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT fanhaiyun theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT wangtao theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT binghamcliftono theeffectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT winthropkevinl effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT silverfieldjoel effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT racewiczarthur effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT nealjeffrey effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT leeeunbong effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT hrycajpawel effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT gomezreinojuan effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT somakoshika effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT mebuscharles effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT wilkinsonbethanie effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT hodgejennifer effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT fanhaiyun effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT wangtao effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis AT binghamcliftono effectoftofacitinibonpneumococcalandinfluenzavaccineresponsesinrheumatoidarthritis |